D. E. Shaw buys $514,553,175 stake in Amgen (AMGN)

Amgen (AMGN) : D. E. Shaw scooped up 446,710 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,973,952 shares of Amgen which is valued at $514,553,175.Amgen makes up approximately 1.06% of D. E. Shaw’s portfolio.

Other Hedge Funds, Including , Davidson Investment Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 67 additional shares and now holds a total of 31,566 shares of Amgen which is valued at $5,461,549. Amgen makes up approx 0.86% of Davidson Investment Advisors’s portfolio.Grantham Mayo Van Otterloo reduced its stake in AMGN by selling 151,216 shares or 98.18% in the most recent quarter. The Hedge Fund company now holds 2,799 shares of AMGN which is valued at $484,283.Rafferty Asset Management reduced its stake in AMGN by selling 5,893 shares or 60.0% in the most recent quarter. The Hedge Fund company now holds 3,929 shares of AMGN which is valued at $677,477. Amgen makes up approx 0.04% of Rafferty Asset Management’s portfolio.Hellman Jordan Management Co Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 930 additional shares and now holds a total of 7,907 shares of Amgen which is valued at $1,363,404. Amgen makes up approx 2.40% of Hellman Jordan Management Co Inc’s portfolio.Gilman Hill Asset Management boosted its stake in AMGN in the latest quarter, The investment management firm added 41 additional shares and now holds a total of 4,411 shares of Amgen which is valued at $730,770. Amgen makes up approx 0.29% of Gilman Hill Asset Management’s portfolio.

Amgen opened for trading at $170.55 and hit $170.56 on the upside on Thursday, eventually ending the session at $170.13, with a gain of 0.04% or 0.07 points. The heightened volatility saw the trading volume jump to 18,76,141 shares. Company has a market cap of $127,319 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *